Faced with a steep cliff of patent expirations for some of its key commercial assets, Novartis has shone a light on its pipeline as it seeks to ease investor fears regarding its growth into the next decade.

The Swiss drugmaker said it expects more than 35 readouts that could enable drug submissions through 2031. Candidates in development span oncology, immunology, neuroscience, and cardiovascular-renal-metabolic. Ten of the assets in late-stage development have multi-billion-dollar peak sales guidance, according to Novartis.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The pipeline overview was revealed to investors in London on 19 November as part of a wider unveiling of the company’s long-term growth trajectory. Novartis projects net sales to grow at a 5% compound annual rate between 2026 and 2031. The guidance marks a slight dip from a previous range of 5-6% from 2025 to 2030.

Novartis is bracing for significant drops in revenue for some of its marketed drugs. Key amongst these is breast cancer treatment Kisqali (ribociclib), which generated $4.78bn in global sales in 2025. GlobalData’s Pharma Intelligence Center predicts peak revenue of nearly $11bn in 2030, before a drop to $6.9bn in 2032 – the year market exclusivity is expected to end in the US.

GlobalData is the parent company of Pharmaceutical Technology.

Along with its potentially blockbuster-filled pipeline, Novartis also pointed to current commercial brands that it expects will fill revenue gaps in the coming years. The company raised peak sales guidance for three key brands – multiple sclerosis treatment Kesimpta (ofatumumab), blood cancer drug Scemblix (asciminib), and lipid-lowering injection Leqvio (inclisiran). Kesimpta is expected to generate the most from these at $8bn, though Novartis did not provide a year.

Novartis CEO Vas Narasimhan said: “In 2026 we expect to grow through the largest loss-of-exclusivity impact in our history.”

Citi analysts called the investor event “upbeat”, highlighting that the sales guidance was above Visible Alpha consensus.  

“[Novartis has] the building blocks to achieve mid-single-digit growth post-2031 despite major loss of exclusivities,” they said in a research note.

They added: “We see the new above-consensus outlooks as positive but expect market to remain sceptical of post-2031 growth pending further pipeline data.”

Alongside in-house R&D, Novartis has sought external innovation. In June, the company outlaid up to $1.9bn in a cancer partnership with Antares Therapeutics. However, Novartis’ corporate structure recently faced scrutiny after trial setbacks rocked investor confidence in the company’s M&A strategy.

Among these was del-desiran’s failure in the Phase III HARBOR study (NCT06411288), evaluating the drug as a treatment in the rare muscle-wasting disease myotonic dystrophy type 1 (DM1). Del-desiran was the flagship product in Novartis’ $12bn acquisition of Avidity Biosciences, which closed in February 2026. Following the readout, a major Novartis shareholder called for a shake-up of the drugmaker’s board to improve corporate governance, though Narasimhan was not blamed.